Travere Therapeutics Inc

TVTX:NASDAQ
RT Quote | NASDAQ | USD
Last | 01/25/21 EST
27.17quote price arrow down-0.50 (-1.81%)
Volume
874,715
52 week range
8.98 - 29.59

...

Loading . . .

KEY STATS

  • Open27.61
  • Day High28.44
  • Day Low25.86
  • Prev Close27.17
  • 52 Week High29.59
  • 52 Week High Date01/15/21
  • 52 Week Low8.98
  • 52 Week Low Date03/18/20
  • Market Cap1,387.03M
  • Shares Out51.05M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta0.66
  • 1 Year % Change66.48

RATIOS/PROFITABILITY

  • EPS (TTM)-2.14
  • P/E (TTM)-12.68
  • Fwd P/E (NTM)-16.57
  • EBITDA (MRQ)-45.87M
  • ROE (MRQ)-35.43%
  • Revenue (MRQ)194.03M
  • Gross Margin (MRQ)97.02%
  • Net Margin (MRQ)-49.97%
  • Debt To Equity (MRQ)70.55%

EVENTS

  • Earnings Date02/26/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Travere Therapeutics Inc News

There is no recent news for this security.

Latest TVTX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor...
Gary Lyons
Chairman
Eric Dube Ph.D.
President
Laura Clague CPA
Chief Financial Officer
Address
3611 Valley Centre Dr, Suite 300
San Diego, CA
92130-3330
United States